Market analysts believe that the combination of the ongoing interest rate cut cycle, accelerated M&A activity by Big Pharma to bolster pipelines, and the integration of AI into drug discovery will support the medium-to-long-term performance of the healthcare sector.

• Policy and Valuation: Franklin Templeton Sinoam notes that industry uncertainty has decreased following Medicare drug price negotiations with the White House. Currently, healthcare valuations remain below their 20-year average, offering significant upside.
• The Patent Cliff: With over $400 billion in revenue facing patent expirations over the next decade, Big Pharma is expected to remain highly active in M&A and licensing. Capital Investment Trust Corp NASDAQ Biotech ETF identifies approximately $200 billion in revenue challenges by 2030 alone as a primary driver for valuation recovery.
• Key Themes: Investment strategies are focusing on four innovative pillars: GLP-1 receptor agonists (obesity/diabetes), novel cardiovascular therapies, oncology bispecific antibodies, and neuroscience.
• AI and Life Science Tools: PGIM highlights that while AI captures market headlines, the healthcare sector’s forward P/E of 18.6x (vs. S&P 500’s 22.2x) represents a defensive yet attractive valuation. Life science tools are identified as a high-growth sub-sector, providing the essential infrastructure for basic research and clinical applications.

Resource: 三大動能 法人看好全球生醫前景